parkinsons | CARLAT PUBLISHING

RESEARCH UPDATE

Can Pimavanserin Treat Psychosis in Patients With Dementia?

October 1, 2022

James Black, MD. Dr. Black, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study suggests that patients started on pimavanserin for dementia and psychosis should probably continue it to prevent relapse, but we will need more data for clarity given flaws in the study design.

Structural Brain Changes: How Imaging Affects Management of Late-Life Psychiatric Conditions

July 1, 2022

Oluwole Jegede, MD, PhD

Olusola Alade Ajilore, MD, PhD

Associate professor, Department of Psychiatry, University of Illinois College of Medicine, Chicago, IL.

Dr. Ajilore, expert for this educational activity, is an employee of KeyWise AI and an advisor for Embodied Labs, Blueprint, and Sage Therapeutics. All of the relevant financial relationships listed for this individual have been mitigated.

When does imaging change management? Dr. Ajilore describes when to order neuroimaging and what to look for. He walks us through various imaging modalities (both structural and functional) that can point us toward the correct diagnosis.

Nuplazid: Novel Mechanism, Modest Benefits

March 30, 2020

Randall Moore, MD, JD. and Chris Aiken, MD.

Randall Moore, MD, JD. Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences at Texas A & M University Health Science Center College of Medicine. Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Moore and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction.

Antipsychotics Fall Short in Delirium

March 30, 2020

Adrienne Grzenda, MD.

Adrienne Grzenda, MD. Dr. Grzenda has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antipsychotics remain a mainstay of delirium treatment despite significant concerns about their safety and efficacy. A pair of reports recently evaluated the evidence on their use in delirium.

What to Know When Diagnosing Parkinsonism

June 7, 2019

In addition to antipsychotics, parkinsonism symptoms can also develop through the use of non-psychiatric medicines, particularly metoclopramide (Reglan), an anti-nausea medicine. Neurologist David M. Kaufman, MD, of Montefiore Medical Center, Bronx, NY. Dr. Kaufman offered the following information in an Expert Q&A from The Carlat Psychiatry Report:What other disorders might...